Get startedLog in
    Picture of Geneuro SA logo

    GNRO — Geneuro SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: Geneuro and Servier announce 6-month results from CHANGE-MS Phase 2b study in multiple sclerosis

    Picture of Geneuro SA logoGeneuro SA
    28/08/2017 06:31
    Aug 28 (Reuters) - GENEURO SA  GNRO.PA : 
    * GENEURO AND SERVIER ANNOUNCE SIX-MONTH RESULTS FROM 
CHANGE-MS PHASE 2B STUDY IN MULTIPLE SCLEROSIS 
    * GNBAC1 IS WELL TOLERATED;  ANTI-INFLAMMATORY EFFECT NOT 
DEMONSTRATED AT 6 MONTHS 
    * ANALYSIS OF FULL 12-MONTH PHASE 2B DATA EXPECTED 1Q18 
 
Source text for Eikon:  ID:nBw5TLNNja  
 
Further company coverage:  GNRO.PA  
 
  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Geneuro SA

    See all news